Oseltamivir Treatment for Influenza Viral Pneumonia

Efficacy and Recommendations

Oseltamivir is a neuraminidase inhibitor effective against both influenza A and B viruses, though it may be less effective against influenza B, as recommended by the Centers for Disease Control and Prevention 3, 1
The Infectious Diseases Society of America recommends that oseltamivir should be used for treating influenza viral pneumonia, even if symptoms have been present for more than 48 hours, particularly in hospitalized patients or those with severe illness 1, 2
Treatment with oseltamivir reduces the risk of pneumonia by approximately 50% compared to placebo in patients with laboratory-confirmed influenza, according to the World Health Organization 3, 4
In hospitalized adults with influenza, antiviral treatment with oseltamivir is warranted even if the radiographic infiltrate is caused by a subsequent bacterial superinfection, as stated by the American Thoracic Society 1

The American College of Chest Physicians recommends that for severely ill patients or immunocompromised patients, treatment is recommended regardless of time since symptom onset 2, 4
Early administration of oseltamivir (within 48 hours of symptom onset) provides the greatest benefit, but treatment should not be withheld in severely ill patients even if beyond this window, as advised by the Infectious Diseases Society of America 2, 1
For hospitalized patients, oseltamivir treatment initiated within 2 days of symptom onset is associated with earlier hospital discharge, according to the Society of Hospital Medicine 2, 4

The Centers for Disease Control and Prevention note that data are limited regarding the effectiveness of oseltamivir in preventing serious influenza-related complications such as pneumonia or for treating influenza among persons at high risk for serious complications 3, 7
Some studies have suggested that oseltamivir might be less effective for influenza B than influenza A, as reported by the World Health Organization 3, 2